Exicure (NASDAQ:XCUR) Trading Down 4.5% – Here’s Why

Exicure, Inc. (NASDAQ:XCUR)’s share price traded down 4.5% during trading on Monday . The stock traded as low as $9.77 and last traded at $10.04. 4,221 shares were traded during trading, a decline of 99% from the average session volume of 574,559 shares. The stock had previously closed at $10.51.

Exicure Price Performance

The firm has a 50-day simple moving average of $11.45 and a 200 day simple moving average of $12.49. The firm has a market cap of $63.43 million, a PE ratio of -4.85 and a beta of 3.86.

Exicure (NASDAQ:XCUR) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Exicure

A hedge fund recently raised its stake in Exicure stock. Carlyle Group Inc. lifted its stake in Exicure, Inc. (NASDAQ:XCUR) by 400.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 281,636 shares of the company’s stock after purchasing an additional 225,308 shares during the quarter. Exicure accounts for approximately 0.9% of Carlyle Group Inc.’s holdings, making the stock its 11th biggest position. Carlyle Group Inc. owned approximately 10.79% of Exicure worth $3,850,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.82% of the company’s stock.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.